Denali Therapeutics (DNLI) Stock Price, News & Analysis

Company Overview

Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing medicines for patients with neurodegenerative diseases. The company’s research programs address conditions involving the central nervous system, including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis and lysosomal storage disorders.

Denali’s drug-discovery approach is built around its Transport Vehicle platform, which is designed to help therapeutic molecules cross the blood-brain barrier and reach the brain. Its pipeline has included small-molecule therapies, biologic medicines and enzyme-replacement treatments targeting disease pathways such as LRRK2, TREM2 and lysosomal dysfunction. The company advances candidates through research and clinical development and has entered into collaborations with larger pharmaceutical companies, including Biogen and Takeda.

Founded in 2013, Denali is headquartered in South San Francisco, California. The company was co-founded by Ryan Watts, Ph.D., who serves as chief executive officer. Its programs are developed for potential use in global markets, with clinical research and collaborations supporting the development of treatments for patients with serious neurological and neurodegenerative conditions.

Key Stats

• Today's Range: $20.51 to $21.09
• 50-Day Range: $19.72 to $25.69
• 52-Week Range: $13.75 to $27.30
• Volume: 2.26 million shs
• Average Volume: 1.67 million shs
• Market Capitalization: $3.30 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $35.85
• Consensus Rating: Moderate Buy

Denali Therapeutics Stock Analysis - MarketRank™

Denali Therapeutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 372nd out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Denali Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 13 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Denali Therapeutics has a consensus price target of $35.85, representing about 73.4% upside from its current price of $20.67.

Amount of Analyst Coverage

Denali Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Denali Therapeutics are expected to grow in the coming year, from ($2.67) to ($2.43) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Denali Therapeutics is -7.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Denali Therapeutics is -7.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Denali Therapeutics has a P/B Ratio of 2.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.87% of the float of Denali Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Denali Therapeutics has a short interest ratio ("days to cover") of 11.97, which indicates bearish sentiment.

Change versus previous month

Short interest in Denali Therapeutics has recently increased by 2.99%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Denali Therapeutics does not currently pay a dividend.

Dividend Growth

Denali Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.97

News Sentiment

Denali Therapeutics has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Denali Therapeutics this week, compared to 4 articles on an average week.

Search Interest

10 people have searched for DNLI on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Denali Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Denali Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $136,507.00 in company stock.

Percentage Held by Insiders

9.70% of the stock of Denali Therapeutics is held by insiders.

Percentage Held by Institutions

92.92% of the stock of Denali Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/30/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:DNLI
• CIK: 1714899
• Web: www.denalitherapeutics.com
• Phone: (650) 866-8547
• Fax: N/A
• Employees: 507
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Denali Therapeutics: $35.85
• High Price Target: $42.00
• Low Price Target: $26.00
• Potential Upside/Downside: +73.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 16 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.84)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$512.54 million
• Net Margins: N/A
• Pretax Margin: -14,188.37%
• Return on Equity: -55.27%
• Return on Assets: -44.24%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 8.37
• Quick Ratio: 8.32

Sales & Book Value

• Annual Sales: $330.53 million
• Price / Sales: 10.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.91 per share
• Price / Book: 2.99

Miscellaneous

• Outstanding Shares: 159,850,000
• Free Float: 144,342,000
• Market Cap: $3.30 billion
• Optionable: Optionable
• Beta: 1.01